Highlights the importance of evaluating secondary causes, providing dietary advice, and carefully considering drug therapy for high-risk patients with persistent hypercholesterolemia.
Requires individualized risk-benefit assessment before drug therapy in persistent hypercholesterolemia; leaves open optimal modern thresholds and long-term safety data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Florkowski et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: